Osphos 51 mg/ml Solution for Injection for Horses

País: Reino Unido

Língua: inglês

Origem: VMD (Veterinary Medicines Directorate)

Ingredientes ativos:

Clodronic Acid

Disponível em:

Dechra Limited

Código ATC:

QM05BA02

DCI (Denominação Comum Internacional):

Clodronic Acid

Forma farmacêutica:

Solution for injection

Tipo de prescrição:

POM-V - Prescription Only Medicine – Veterinarian

Grupo terapêutico:

Horses

Área terapêutica:

Musculoskeletal

Status de autorização:

Authorized

Data de autorização:

2015-09-02

Características técnicas

Revised: February 2021
AN: 01364/2019
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Osphos 51 mg/ml Solution for Injection for Horses
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml contains:
Active substance:
Clodronic acid
51.00 mg
(Equivalent to clodronate disodium tetrahydrate 74.98 mg)
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless solution, practically free from visible particles.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the alleviation of clinical forelimb lameness associated with the
bone resorptive
processes of the distal sesamoid (navicular bone) in adult horses.
4.3
CONTRAINDICATIONS
Do not administer intravenously.
Do not use in horses less than 4 years of age, due to the absence of
data regarding
use in growing animals.
Do not use in horses with impaired renal function.
Do not use in cases of known hypersensitivity to the active substance
or to any of the
excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
The veterinary medicinal product should be used only after a proper
diagnosis
combining a complete orthopaedic clinical examination including local
analgesia and
appropriate imaging techniques, in order to identify the cause of pain
and the nature
of bone lesions.
Clinical improvement in lameness grade may not be accompanied by
radiographic
changes in the appearance of the navicular bone.
Revised: February 2021
AN: 01364/2019
Page 2 of 5
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals:
Use caution when administering bisphosphonates to horses with
conditions affecting
mineral or electrolyte homeostasis, e.g. hyperkalaemic periodic
paralysis,
hypocalcaemia.
Adequate access to drinking water should be provided when using the
product. If
uncertainty exists about renal function, renal parameters should be
assessed before
administration of the product. Water consumption and urine output
should be